ProfileGDS4814 / ILMN_1669700
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 78% 79% 81% 76% 79% 79% 77% 78% 77% 80% 76% 74% 78% 79% 77% 77% 78% 77% 76% 78% 78% 77% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)118.44878
GSM780708Untreated after 4 days (C2_1)136.86179
GSM780709Untreated after 4 days (C3_1)156.31281
GSM780719Untreated after 4 days (C1_2)107.36376
GSM780720Untreated after 4 days (C2_2)130.92879
GSM780721Untreated after 4 days (C3_2)136.16179
GSM780710Trastuzumab treated after 4 days (T1_1)115.9677
GSM780711Trastuzumab treated after 4 days (T2_1)121.10478
GSM780712Trastuzumab treated after 4 days (T3_1)115.8377
GSM780722Trastuzumab treated after 4 days (T1_2)140.29780
GSM780723Trastuzumab treated after 4 days (T2_2)102.37176
GSM780724Trastuzumab treated after 4 days (T3_2)93.604974
GSM780713Pertuzumab treated after 4 days (P1_1)127.15378
GSM780714Pertuzumab treated after 4 days (P2_1)137.20779
GSM780715Pertuzumab treated after 4 days (P3_1)112.64877
GSM780725Pertuzumab treated after 4 days (P1_2)117.15777
GSM780726Pertuzumab treated after 4 days (P2_2)124.4278
GSM780727Pertuzumab treated after 4 days (P3_2)111.86477
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)104.63176
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)122.32678
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)120.06378
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)116.89377
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)110.89377